Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGICA
NCT06037460Phase 3Active, not recruiting
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- May 2024
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of tocilizumab in giant cell arteritis (GCA), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Started May 2024; status: active, not recruiting.
02
Drugs
tocilizumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on NCT06037460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06037460.